Stereotactic radiosurgery boost to the resection cavity for cerebral metastases: Report of overall survival, complications, and corticosteroid protocol

Robert G. Kellogg, David C. Straus, Mehee Choi, Thymur A. Chaudhry, Aidnag Z. Diaz, Lorenzo F. Muñoz

Departments of Neurosurgery, and Radiation Oncology, Rush University Medical Center, Chicago, IL, Department of Radiation Oncology, Loyola University Medical Center, Maywood, IL, Medical College, Rush University, Chicago, IL, USA

E-mail: Robert G. Kellogg - robert_kellogg@rush.edu; David C. Straus - david_straus@rush.edu; Mehee Choi - mehee.choi@gmail.com; Thymur A. Chaudhry - thymur_a_chaudhry@rush.edu; Aidnag Z. Diaz - aidnag_diaz@rush.edu; Lorenzo F. Muñoz - lorenzo_munoz@rush.edu

*Corresponding author

Received: 28 June 13  Accepted: 21 August 13  Published: 20 November 13

Abstract

Background: This report focuses on the overall survival and complications associated with treatment of cerebral metastases with surgical resection followed by stereotactic radiosurgery (SRS). Management and complications of corticosteroid therapy are underreported in the literature but represent an important source of morbidity for patients.

Methods: Fifty-nine consecutive patients underwent surgical resection of a cerebral metastasis followed by SRS to the cavity. Patient charts were reviewed retrospectively to ascertain overall survival, local control, surgical complications, SRS complications, and corticosteroid complications.

Results: Our mean follow-up was 14.4 months (median 12.0 months, range 0.9-62.9 months). Median overall survival in this series was 15.25 months and local control was 98.3%. There was a statistically significant survival benefit conferred by Radiation Therapy Oncology Group recursive partitioning analysis Classes 1 and 2. The surgical complication rate was 6.8% while the SRS complication rate was 2.4%. Corticosteroid complications are reported and dependence at 1 month was 20.3%, at 3 months 6.8%, at 6 months 1.7%, and at 12 months no patients remained on corticosteroid therapy.

Conclusions: Overall survival and local control with this treatment paradigm compare well to the other published literature. Complications associated with this patient population are low. A corticosteroid tapering protocol is proposed and demonstrated lower rates of steroid-related complications and dependence than previously reported.

Key Words: Cerebral metastases, corticosteroids, stereotactic radiosurgery

INTRODUCTION

Cerebral metastasis is the most common intracranial tumor in the adult population and the incidence is rising. As many as 40% of cancer patients will develop cerebral metastases during their disease course,
combined with enhanced detection capabilities and cancer therapies that extend overall life expectancy, makes the treatment of cerebral metastases an important consideration in modern cancer therapy.[28]

Historically, cerebral metastases were managed with palliative therapy and were considered the end stage of a patient’s disease.[52] This improved with the introduction of corticosteroid therapy in the 1960s[8] and improved again with the subsequent addition of whole brain radiation therapy (WBRT).[33] Currently, management consists of a combination of surgery, WBRT, and stereotactic radiosurgery (SRS), and the specific regimen is tailored to each patient and the preferences of the treating physician.[3,34-36] There is evidence that surgical resection followed by SRS to the resection cavity may provide superior local control rates as compared with standard therapy, notwithstanding a higher rate of distant recurrence.[17,22,31,38] Recent interest has focused on the utility of SRS for patients with oligometastatic disease.[37,42]

Corticosteroid use for the management of symptomatic peritumoral edema is a mainstay of treatment.[40] Dexamethasone is the most commonly chosen agent given its potent anti-inflammatory properties and lack of mineralocorticoid activity.[4] However, corticosteroids can have harmful side effects such as hyperglycemia, Cushing’s syndrome, psychiatric symptoms, osteoporosis, and steroid myopathy among others.[40] These side effects represent a significant source of morbidity. Hyperglycemia, for example, has been associated with decreased overall survival when it persists greater than 3 months after surgical resection.[26] Weissman et al. found that 51% (30/59) of patients suffered at least one steroid toxicity and 19% (11/59) were hospitalized secondary to corticosteroid-related complications.[52] Current recommendations regarding the termination of corticosteroid therapy state only that the agent should be tapered over a 2 week period or longer if clinically indicated.[41]

The present study examines the overall survival and complications for patients with cerebral metastases treated by surgical resection followed by SRS to the cavity. We also propose a protocol for the management of corticosteroid therapy in this population.

**MATERIALS AND METHODS**

During a 2-year period from 2010 to 2012, 59 consecutive patients who underwent surgical resection of a cerebral metastasis followed by SRS to the resection cavity were identified. This time period was selected because it represents the initiation of this protocol to the start of the study period. Metastatic lesions at our institution are treated exclusively by the two senior authors (LM and AD) and the cases selected were identified from a prospectively maintained database.

Patient information was obtained from the hospital chart and outpatient records from the Departments of Neurosurgery, Oncology, and Radiation Oncology. This work was conducted as part of studies approved by the institutional review board at Rush University Medical Center (Chicago, IL) (ORA #12121105-IRB01-AM02).

Seven patients had received prior cranial radiation therapy and were offered surgery because of the development of new intracranial lesions. The SRS was delivered to the operative bed within 1 month of surgery in most cases. The patient records were reviewed retrospectively and data regarding the following variables were recorded: age, sex, primary pathology, extent of extracranial disease (based on preoperative staging enhanced computed tomography scan (CT) of the chest, abdomen, and pelvis), the number and size of cerebral metastases, extent of resection (gross vs. subtotal as evidenced by 24-hour postoperative magnetic resonance imaging (MRI) scan), post operative complications, duration of corticosteroid use, corticosteroid-related complications, and SRS dose and treatment volume. Additionally, all patients were classified according to the Radiation Oncology Therapy Group (RTOG) Recursive Partitioning Analysis (RPA).[9]

The prerequisite for neurosurgical treatment was stable systemic disease and life expectancy greater than 6 months as determined by the patient’s oncologist. The choice to proceed with surgical resection was made based upon lesion size, peritumoral edema, and presence of mass effect and/or symptoms. The lesions were all classified by the Sawaya criteria:[40] Grade I lesions are located in noneloquent brain, Grade II lesions in near-eloquent brain, and Grade III lesions in eloquent brain. Eloquent locations in the Sawaya study are the motor/sensory cortices, visual center, speech center, internal capsule, basal ganglia, hypothalamus/thalamus, brainstem, and dentate nucleus.[41]

All patients underwent craniotomy and resection with the assistance of preoperative MRI images for frameless stereotactic guidance. After surgery, a new MRI brain was obtained for SRS planning. Patients were generally mobilized on postoperative day #1 and were seen as outpatients by neurosurgery between 2 and 4 weeks after surgery. SRS typically was given within one month of surgery. Post-SRS patients were seen initially at 6 weeks and then every 3 months with repeat MRI studies at each visit. Additional or expedited neuroimaging was obtained if central nervous system-related signs or symptoms developed. The patient’s oncologist provided all systemic cancer care.

On the day of SRS, a stereotactic head frame was placed under local anesthesia and a simulation CT of the head obtained and fused with the MRI scan. The edges of the operative bed were delineated by the neurosurgeon and radiation oncologist on the MR images. Treatment plans for patients treated before March 2012 were designed using a conformal arc technique on a Varian
Trilogy linear accelerator with a Brainlab treatment planning system (Westchester, IL). After March 2012 treatments were conducted on a Varian TruBeam STx (Palo Alto, CA) system with the Brainlab treatment planning system (Westchester, IL) and a frameless technique. All surgical cavities were treated with 1500 to 1600 cGy, and dose selection was based upon the RTOG 90-05 volume dependent SRS guidelines.[44]

Follow-up MRI scans were obtained 1 month after treatment and at 2 to 3 month intervals thereafter. If up to four new lesions were identified on follow-up imaging, they were treated with SRS using the RTOG 90-05 dose/volume scheme[44] if they were larger than 2 cm. For lesions smaller than 2 cm, a dose of 2100 cGy was used. If more than four new lesions were identified, we recommended proceeding with WBRT.

A corticosteroid tapering protocol was utilized that enables patients to be discontinued from this therapy in a timely fashion. The MRI scans of all patients are evaluated for the degree of cerebral edema surrounding a given metastasis, and this is one of the variables considered when deciding to proceed with surgical resection. Patients are started on dexamethasone 4 mg every 6 hours until the first postoperative day. At that time the dose is reduced to dexamethasone 4 mg every 12 hours and then dexamethasone 2 mg every 12 hours the next day. On postoperative day 3 the dose is reduced to 2 mg daily until SRS is completed. After SRS all patients are sent home with a methylprednisolone dose pack that contains 21 tablets of 4 mg each; the dosing regimen can be found in Table 1. The goal is to discontinue corticosteroid therapy after the completion of the methylprednisolone dose pack.

Complications were surgical if they occurred within 30 days or, if later than 30 days, were a direct result of surgical intervention. Complications were transient if they resolved within 30 days of surgery or definitive management, or prolonged if they persisted until last follow-up or death. The criteria proposed by Sawaya et al. for classifying complications is applied.[43]

Overall survival and local control were determined by the method of Kaplan and Meier.[21] Statistical significance was considered as $P < 0.05$. The log-rank test was used as the test statistic for comparing median overall survival across groups. Kaplan-Meier Curves, median survival, confidence intervals, and Cox-proportional hazard-ratios were calculated using STATA v9.2 (College Station, TX).

RESULTS

Fifty-nine consecutive patients were treated in the above manner. We present the overall survival (OS), local control (LC), and treatment-related complications for this group of patients.

The tumors originated from different primary cancers [Table 2]. In 27 out of the 59 patients (46%) multiple metastases were identified while the remaining 32 patients (54%) had only a solitary lesion. There were 29 men and 30 women with a mean age of 61 years. Tumor histology is as follows: 3 breast carcinoma, 1 cervical carcinoma, 1 colon adenocarcinoma, 3 head/neck squamous cell carcinoma, 9 melanoma, 38 nonsmall cell lung carcinoma (NSCLC), 1 renal cell carcinoma, 2 sarcoma, and 1 small cell lung carcinoma. The average tumor diameter was 2.5 cm with the largest being 5.8 cm and the smallest 0.8 cm. Fifteen patients (25%) were classified as RPA Class 1, 37 (63%) as RPA Class 2, and 7 (12%) as RPA Class 3.

Table 1: Dosing schedule for the methylprednisolone dose pack

| Dosing regimen for methylprednisolone dose pack |
|-----------------------------------------------|
| Day 1: Two tablets before breakfast, one after lunch, one after dinner, and two at bedtime |
| Day 2: One tablet before breakfast, one after lunch, one after dinner, and two at bedtime |
| Day 3: One tablet before breakfast, one after lunch, one after dinner, and one at bedtime |
| Day 4: One tablet before breakfast, one after lunch, and one at bedtime |
| Day 5: One tablet before breakfast and one at bedtime |
| Day 6: One tablet before breakfast |

Table 2: Patient characteristics

| Characteristic                  | Number |
|--------------------------------|--------|
| Sex (%)                        |        |
| M                              | 29     |
| F                              | 30     |
| Age at treatment               | 61.2 years (range 29-88) |
| Primary tumor type             |        |
| NSCLC                          | 38     |
| Melanoma                       | 9      |
| Small cell lung cancer         | 1      |
| Head/neck squamous cell carcinoma | 3    |
| Sarcoma                        | 2      |
| Renal cell carcinoma           | 1      |
| Breast carcinoma               | 3      |
| Cervical cancer                | 1      |
| Colon adenocarcinoma           | 1      |
| Mean corticosteroid use (weeks)| 3.4    |
| RPA Class                      |        |
| 1                              | 15     |
| 2                              | 37     |
| 3                              | 7      |
| Sawaya grade                   |        |
| I                              | 25     |
| II                             | 17     |
| III                            | 17     |

M: Male, F: Female, NSCLC: Non-small cell lung carcinoma, RPA: Recursive partitioning analysis
7 (12%) as RPA Class 3. Thirty-three of 59 patients (56%) had distant metastases at the time of initial resection.

Operative complications are presented in Table 3. There was one case of an acute subdural hematoma that developed in the immediate postoperative period and required emergent evacuation after resection of a melanoma metastasis. One patient suffered new-onset diplopia after surgery, one patient had a worsened hemiparesis, and there was one case of a wound infection. Additionally, one patient developed a deep venous thrombosis (DVT) and pulmonary embolism (PE) in the 30-day postoperative period that required treatment. The overall neurological/regional complication rate was 6.8%. The systemic complication rate was 1.7%. There were two complications associated with SRS therapy in this series (2.4%).

Patients underwent SRS treatment at a mean of 3.5 weeks (1-224 days) after surgery. The postoperative bed was treated with a mean dose of 1600 cGy (range 1500 cGy in a single fraction to 3000 cGy given in 5 fractions) to the 90% isodose line. The mean target volume was 13.1 cm³. Three thousand centigray in 5 fractions were used when the target volume was equivalent to a sphere larger than 3 cm in diameter.

Mean follow-up was 14.4 months (median 12.0 months, range 0.9-62.9 months). The median OS was 15.25 months (95% CI: 11.74-24.20 months) [Figure 1]. Overall survival was 15.95 months in RPA class 1, 15.48 months in RPA class 2, and 8.38 months in RPA class 3 [Figure 2]. The Cox-proportional hazards ratio (HR) was 2.54 (95% CI 1.03-6.26) for RPA Class 3. There was no difference in median overall survival between RPA class 1 and 2 ($P = 0.6107$). A single patient experienced local recurrence of disease subsequent to SRS, which occurred at 44 days post-SRS, and 5.9 months post resection; this recurrence was treated with a second SRS procedure.

Corticosteroid protocol
Corticosteroids in the form of dexamethasone were given to all patients in the immediate preoperative period and then rapidly tapered postoperatively. Thereafter, the radiation oncologist managed the corticosteroid regimen. A standard methylprednisolone dose pack (6 days of therapy) was given to all patients after SRS treatment. All patients received gastrointestinal (GI) prophylaxis in the form of a proton pump inhibitor or H2-blocker. The mean duration of corticosteroid use from the time of diagnosis before surgery to after completion of SRS treatment was 3.4 weeks. At 1 month, 12 patients (20.3%) remained on corticosteroids, at 3 months 4 patients (6.8%), at 6 months 1 patient (1.7%), and at 12 months no patients remained on corticosteroid therapy. The reasons patients were maintained on corticosteroids past the end point of our protocol was due to peritumoral edema seen on MRI scan (8 patients), worsening neurological deficit upon wean (3 patients), and leptomeningeal disease (1 patient).

Complications related to corticosteroid therapy were seen in 91.5% of patients (54/59) and most commonly occurred in the form of hyperglycemia (34/59 patients, 57.6%). Peripheral edema and depression occurred in six patients each (10.2%). There were four (6.8%) DVT and one case (1.7%) of a PE. One patient (1.7%) experienced delayed wound healing, one patient had pneumonia, and there was one GI bleed. There were no cases of oropharyngeal candidiasis, gastritis, Cushing’s syndrome,
steroid psychosis, or steroid myopathy. A full listing of corticosteroid-related complications is found in Table 4.

DISCUSSION

The use of adjuvant WBRT following resection in patients with cerebral metastases has been the standard of care,[56] but recently treatment with SRS to the resection cavity has been explored.[17,22,31,38] The rationale for adjuvant SRS in lieu of WBRT is to maintain the local control benefits of radiation and surgery while avoiding the now-recognized deleterious cognitive effects of WBRT[5] and maintaining comparable overall survival with this approach.[11]

The local control rate at 1 year observed in this study, 98.3% (1 recurrence), compares favorably to the published literature. Karlovits et al. reported a local control of 92.5% while Robbins et al., reported 81.2%. Both the studies were conducted retrospectively and contained patients who had undergone surgical resection followed by SRS. Hartford et al. reported on a similar group with a local control rate of 85.5%. [11]

Overall survival in this series was 15.25 months and compares well to the literature. Most contemporary series report an OS of 10-20 months.[6,14,16,17,22,31,46] This also compares well with the combined results from prior randomized-controlled trials of various alternate treatment regimens: Surgical Resection + WBRT (median OS 9.07 months), SRS + WBRT (median OS 8.07 months), and WBRT alone (median OS 5.95 months).[10,19,20,24] In our data set we found significantly greater OS in patients who were RPA Class 1 or 2. In this group (n = 52) median OS was 15.94 months, while median OS in RPA Class 3 patients was 8.38 months (P = 0.0358).

Salvage WBRT was required in 42.4% of patient in this study and in all cases was due to the detection of new distant metastases. There was no statistically significant factor associated with this but it can be attributed to the inevitable progression of the disease course.

Corticosteroids remain a mainstay of therapy for cerebral metastases and their effectiveness at reducing symptoms from cerebral edema in this patient population is well documented.[8,12,15,16,27,40,41,47,49] Our group considers the discontinuation of corticosteroid therapy as a primary goal of care in addition to prolonging OS and minimizing complications. Patients seen by our group who have evidence of significant cerebral edema on MRI scan will be more likely to receive surgical resection of their metastasis because we feel that the risk of corticosteroid dependence will be reduced with this approach.

The corticosteroid tapering protocol implemented by our group has proven to be very effective at weaning patients from this therapy. There are very few other reports in the literature that address this topic[48] although there are abundant recommendations to taper corticosteroids as quickly as possible.[12,18,40,41,45,47] Corticosteroids are often continued for long periods in patients who harbor lesions in eloquent brain;[25] our experience with surgical treatment of these lesions has been previously published.[30]

Side effects of corticosteroid therapy and their impact on the patient are important considerations as they are frequent and confer morbidity.[12,40,52] They include hyperglycemia, DVT/PE formation, poor wound healing, gastritis and GI bleeds, iatrogenic Cushing’s syndrome, and steroid myopathy. Another important, but often not considered, side effect is steroid psychosis.[19] Steroid myopathy is often overlooked in cancer patients who are receiving corticosteroids because the symptoms can be misidentified as secondary to progression of disease; however, this entity is relatively common, severely debilitating, and may be reversible with discontinuation of the agent.[2]

The overall prevalence of side effects in this study is high (91.5% of patients). This is expected in a patient population treated with high-dose dexamethasone. The incidence of specific side effects such as hyperglycemia, DVT, and PE are in line with what literature has been published on the topic.[12] Notably, there are no cases of Cushing’s syndrome, steroid psychosis, or steroid myopathy in this series; these complications carry a high morbidity for the patient. It is also important to note that the incidence of steroid dependence is very low: 20.3% at 1 month, 6.8% at 3 months, 1.7% at 6 months, and 0% at 12 months. To our knowledge, no other series of patients receiving SRS after resection with such data has been published. Williams et al. reported that, in their large series of patients who received only SRS, corticosteroid dependency was associated with 32% of cases overall and was present in 8% of patient

Table 4: Corticosteroid side effects

| Side Effect                   | Number | %    |
|------------------------------|--------|------|
| Hyperglycemia                | 34     | 57.6 |
| Peripheral edema             | 6      | 10.2 |
| Depression                   | 6      | 10.2 |
| Deep venous thrombosis       | 4      | 6.8  |
| Pulmonary embolism           | 1      | 1.7  |
| Delayed wound healing        | 1      | 1.7  |
| GI bleed                     | 1      | 1.7  |
| Gastritis                    | 0      | 0    |
| Pneumonia                    | 1      | 1.7  |
| Cushing’s syndrome           | 0      | 0    |
| Oropharyngeal candidiasis    | 0      | 0    |
| Steroid myopathy             | 0      | 0    |

GI: Gastrointestinal
Our results demonstrate that tailoring therapy to maximize the likelihood of corticosteroid discontinuation reduces dependence and, thus, long-term and serious complications associated with this therapy.

**Surgical complications**

The complication rate as related to surgery was 6.8% in this series and compares well to that reported by Sawaya et al. There is little reported in the literature on surgical complication rates in these patients. Jensen et al. reported only two cases out of a series of 106 patients that experiences a complication; one was the development of hydrocephalus postoperatively and the other was a CSF fistula. Veicht et al. described one intracranial hematoma and three postoperative wound infections in a series of 65 patients. Mintz et al. reported three postoperative hematomas and one wound infection identified via a Cochrane review. Two of the complications in this series required further surgery. All complications are presented in Table 3. Patient 1 in Table 2 required immediate evacuation of an acute SDH after resection of a melanoma metastasis. The complication was promptly diagnosed when he exhibited worsened mental status and a hemiparesis upon emergence from anesthesia. He suffered no permanent neurological sequelae. Patient 2 in Table 2 had undergone resection of a cerebellar metastasis and presented 6 weeks after surgery with dehiscence of the suboccipital incision. Intraoperative cultures grew methicillin resistant *Staphylococcus aureus* (MRSA). He underwent revision of the wound and completed a course of vancomycin. Patient 5 in Table 2 was diagnosed with a DVT/PE 2 weeks after surgery and was cleared to undergo anticoagulation therapy. These results show that surgical complications for this patient population can be held in line with the published literature on the topic.

**SRS complications**

There were two complications associated with SRS therapy in this series (2.4%). One patient developed a MRSA infection in the head frame pin site and underwent a course of antibiotics. Another patient who harbored a pontine metastasis that was not resected and was treated concurrently with the resection cavity experienced exacerbation of a preexisting hemiparesis. This complication rate is lower than other published reports that utilized SRS without surgical resection. This may be due to the lower dose of radiation needed to treat the resection cavity alone versus treating an unresected lesion. Radiation doses required for treatment of unresected lesions can be more than 2000 cGy while doses needed for salvage therapy are even higher. Other studies such as that by Williams et al., reported a complication rate of 40% while Yamamoto et al. reported a long-term complication rate after SRS alone of 10.2%. Studies examining short-term results of SRS therapy without surgery have reported complication rates of 2%. Our results support our belief that resecting metastases prior to delivering SRS reduces the complication rate of this therapy.

Cerebral metastases can be treated with a variety of modalities. While the standard of care for resected lesions remains postoperative WBRT, SRS to the resection cavity has been shown to be effective with a better side effect profile. Corticosteroid therapy is a cornerstone of treatment for symptomatic metastases but has significant side effects. The corticosteroid tapering protocol used at our institution has been effective at reducing corticosteroid dependency in this patient population.

**REFERENCES**

1. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Deep venous thrombosis plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 2006;295:2483-91.
2. Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology 1997;48:1234-8.
3. Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, et al. Central nervous system cancers. J Natl Compr Canc Netw 2011;9:352-400.
4. Chamberlin P, Meyer WJ 3rd. Management of pituitary-adrenal suppression secondary to corticosteroid therapy. Pediatrics 1981;67:245-51.
5. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation. A randomized controlled trial. Lancet Oncol 2009;10:1037-44.
6. Do L, Petzer R, Radany E, Liu A, Staud C, Badie B. Resection followed by stereotactic radiosurgery to resection cavity for intracranial metastases. Int J Radiat Oncol Biol Phys 2009;73:486-91.
7. Elliott RE, Rush S, Morsi A, Mehla N, Spriet J, Narayana A, et al. Neurological complications and symptom resolution following Gamma Knife surgery for brain metastases 2 cm or smaller in relation to eloquent cortices. J Neurosurg 2010;113 Suppl:533-44.
8. Galicich JH, French LA, Melby JC. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. J Lancet 1961;81:46-53.
9. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-51.
10. Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2009;94:17-32.
11. Hartford AC, Paravati AJ, Spire WJ, Li Z, Jarvis LA, Fadul CE, et al. Postoperative stereotactic radiosurgery without whole-brain radiation therapy for brain metastases: Potential role of preoperative tumor size. Int J Radiat Oncol Biol Phys 2013;85:650-5.
12. Hempen C, Weiss E, Hess C. Dexamethasone treatment in patients with brain metastases and primary brain tumors: Do the benefits outweigh the side-effects? Support Care Cancer 2002;10:322-8.
13. Hoskin PJ, Crow J, Ford HT. The influence of extent and local management on the outcome of radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys 1990;19:1115-9.
14. Hwang SW, Abozed MM, Hale A, Eisenberg RL, Dvorak T, Yao K, et al. Adjuvant Gamma Knife radiosurgery following surgical resection of brain metastases: A 9-year retrospective cohort study. J Neurooncol 2010;98:77-82.
15. Ito U, Reulen HJ, Tomita H, Ikeda J, Saito J, Maehara T. Formation and propagation of brain oedema fluid around human brain metastases. A CT Study. Acta Neurochir (Wien) 1988;90:35-41.
16. Iwai Y, Yamanaka K, Yasui T. Boost radiosurgery for treatment of brain metastases after surgical resections. Surg Neurol 2008;69:181-6; discussion 186.
17. Jensen CA, Chan MD, McCoy TP, Bourland JD, deGuzman AF, Ellis TL, et al. Cavity-directed radiosurgery as adjuvant therapy after resection of a brain metastasis. J Neurosurg 2011;114:1585-91.
18. Kaal EC, Taphoorn MJ, Vecht CJ. Symptomatic management and imaging of brain metastases. J Neurooncol 2005;75:15-20.
19. Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, et al. The role of surgical resection in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2009;96:33-43.
20. Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, et al. The role of surgical resection in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2009;96:33-43.
21. Kaplan IW, Meier R. Submucous lipoma of the colon. Am J Gastroenterol 1959;31:673-83.
22. Karlovits BJ, Quigley MR, Karlovits SM, Miller L, Johnson M, Gayou O, et al. Stereotactic radiosurgery boost to the resection bed for oligometastatic brain disease: Challenging the tradition of adjuvant whole-brain radiotherapy. Neurosurg Focus 2009;27:E7.
23. Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD. Radiosurgery with or without whole-brain radiotherapy for brain metastases. Am J Clin Oncol 2005;28:173-9.
24. Linskey ME, Andrews DW, Asher AL, Burri SH, Cobbs CS, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2009;96:45-68.
25. Maldau MV, Aguiar PH, Lang F, Suki D, Wildrick DM, Sawaya R. Radiosurgery in the treatment of brain metastases: Critical review regarding complications. Neurosurg Rev 2008;31:1-8; discussion 8-9.
26. Mcgirt MJ, Chaiichana KL, Gathini M, Attenerolo F, Than K, Ruiz AJ, et al. Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery 2008;63:286-91; discussion 291.
27. Millar BM, Bezjak A, Tsao M, Sturdza A, Laperriere N. Defining the impact and contribution of steroids in patients receiving whole-brain irradiation for cerebral metastases. Clin Oncol (R Coll Radiol) 2004;16:339-44.
28. Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, et al. Stereotactic radiosurgery for brain metastases: Analysis of outcome and risk of brain radioonecrosis. Radiat Oncol 2011;6:48.
29. Mintz A, Perry J, Spithoff K, Chambers A, Laperriere N. Management of single brain metastasis: A practice guideline. Curr Oncol 2007;14:131-43.
30. Munoz L, Kellogg R. Selective excision of cerebral metastases from the precentral gyrus. Surg Neurol Int 2013;4:66.
31. Ogwara H, Kakakota K, Rakhaa SS, Helenowski JB, Marymont MH, Kalaparakal JA, et al. Intracranial relapse rates and patterns, and survival trends following post-resection cavity radiosurgery for patients with single intracranial metastases. J Neurooncol 2012;108:141-6.
32. Oken MM, Creech RH, Torney DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:469-55.
33. Order SE, Hellman S, von Essen CF, Kligerman MM. Improvement in quality of survival following whole-brain irradiation for brain metastasis. Radiology 1968;91:149-53.
34. Paek SH, Audo PB, Sperling MR, Cho J, Andrews DW. Reevaluation of surgery for the treatment of brain metastases: Review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosururgical techniques. Neurosurgery 2005;56:1021-34; discussion 1021-34.
35. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 1998;280:1485-9.
36. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500.
37. Rava P, Leonard K, Sioshansi S, Curran B, Wazer DE, Cosgrove GR, et al. Survival among patients with 10 or more brain metastases treated with stereotactic radiosurgery. J Neurosurg 2013;119:457-62.
38. Robbins JR, Ryu S, Kalkanis S, Cogan C, Rock J, Movsas B, et al. Radiosurgery to the surgical cavity as adjuvant therapy for resected brain metastases. Neurosurgery 2012;71:937-43.
39. Ross DA, Cetas JS. Steroid psychosis: A review for neurosurgeons. J Neurooncol 2012;109:439-47.
40. Ryan R, Booth S, Price S. Corticosteroid-use in primary and secondary brain tumour patients: A review. J Neurooncol 2011;106:449-59.
41. Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, et al. The role of steroids in the management of brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2009;96:103-14.
42. Salvetti DJ, Nagaraja TG, McNeill IT, Xu Z, Sheehan J. Gamma Knife surgery for the treatment of 5 to 15 metastases to the brain. J Neurooncol 2013;118:1250-7.
43. Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, Shi WM, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 1998;42:1044-55; discussion 1055-6.
44. Shaw E, Scott C, Souhani L, Dinapoli R, Kline R, Loeffler J, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 2000;47:291-8.
45. Soffietti R, Cornu P, Delatte Y, Grant R, Graus F, Grisold W, et al. EPNS Guidelines on diagnosis and treatment of brain metastases: Report of an EPNS Task Force. Eur J Neurol 2006;13:674-81.
46. Soltys SG, Adler JR, Lipani JD, Jackson PS, Choi CY, Puataweepong P, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 2008;70:187-93.
47. Sturdza A, Millar BA, Banz N, Laperriere N, Pond G, Wong RK, et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer 2008;16:1041-8.
48. Thomson AH, Tomlinson MJ. Brain metastases and steroid reduction after radiotherapy. Palliat Med 2004;18:665-6.
49. Tsao MN, Khuntia D, Mehta MP. Brain metastases: What’s new with an old problem? Curr Opin Support Palliat Care 2012;6:85-90.
50. Varlooto JM, Flickinger JC, Niranjan A, Bhatnagar AK, Kondziolka D, Lunsford LD. Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2003;57:452-64.
51. Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, et al. Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery. Ann Neurol 1993;33:583-90.
52. Weissman DE, Dufer D, Vogel V, Abeloff MD. Corticosteroid toxicity in neuro-oncology patients. J Neurooncol 1987;5:125-8.
53. Williams BJ, Suki D, Fox DB, Pelloski CE, Maldau MV, Sawaya RE, et al. Stereotactic radiosurgery for metastatic brain tumors: A comprehensive review of complications. J Neurosurg 2009;111:439-48.
54. Yamamoto M, Kawabe T, Higuchi Y, Sato Y, Nariai T, Barford BE, et al. Delayed complications in patients surviving at least 3 years after stereotactic radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2013;85:1021-34.
55. Yamamoto M, Kawabe T, Sato Y, Higuchi Y, Nariai T, Barford BE, et al. A case-matched study of stereotactic radiosurgery for patients with multiple brain metastases: Comparing treatment results for 1-4 vs ≥5 tumors. J Neurosurg 2013;118:1258-68.
56. Yomo S, Hayashi M. The efficacy and limitations of stereotactic radiosurgery as a salvage treatment after failed whole brain radiotherapy for brain metastases. J Neurooncol 2013;113:459-65.